BioCentury
ARTICLE | Finance

Planting seeds

How Apple Tree Partners hopes to use open-ended fund to build a large cap biotech

July 6, 2017 7:10 PM UTC

With a $1.5 billion open-ended fund, Apple Tree Partners is plowing large sums into a handful of translational start-ups with the goal of eventually having at least one portfolio company grow into a commercial-stage large cap.

The firm’s latest investment from Apple Tree Partners IV came June 23, when it led a $50 million series B round in autoimmune company Syntimmune Inc. The firm, which contributed $48 million in the deal, also co-led Syntimmune’s $26 million series A. ...

BCIQ Company Profiles

Syntimmune Inc.